Metachromatic Leukodystrophy (MLD) Treatment Market

Metachromatic Leukodystrophy (MLD) Treatment Market - Global Industry Assessment & Forecast

Healthcare

# Pages:

215

Base Year:

2024

Jan - 2025

Format:

Report Code:

VMR-4065

Segments Covered

By Type Late Infantile MLD, Juvenile MLD, Adult MLD
By Diagnosis Blood tests, Genetic tests, Nerve Conduction Study, Magnetic Resonance Imaging (MRI), Psychological and Cognitive Tests, Others
By Treatment Type AGT-183, GSK-2696274, DUOC-01, Others
By End User Hospital, Clinic, Others
By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Standard License

$ 4099 USD

Multi User License

$ 5250 USD

Enterprise License

$ 6400 USD

Snapshot

Base Year:	2024
Forecast Years:	2025 - 2035
Historical Years:	2019 - 2023
Revenue 2024:	USD 2.3 Billion
Revenue 2035:	USD 4.11 Billion
Revenue CAGR (2025 - 2035):	5.4%
Fastest Growing Region (2025 - 2035)	Asia Pacific
Largest Region (2024):	North America

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst

Executive Dashboard
1. Strategic Imperatives
Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Global Metachromatic Leukodystrophy (MLD) Treatment Market - Segment Analysis
1. Overview
2. Global Metachromatic Leukodystrophy (MLD) Treatment Market, 2016 - 2028 (USD Million)
3. Global Metachromatic Leukodystrophy (MLD) Treatment Market - by Type
  1. By Late Infantile MLD
  2. By Juvenile MLD
  3. By Adult MLD
4. Global Metachromatic Leukodystrophy (MLD) Treatment Market - by Diagnosis
  1. By Blood tests
  2. By Genetic tests
  3. By Nerve Conduction Study
  4. By Magnetic Resonance Imaging (MRI)
  5. By Psychological and Cognitive Tests
  6. By Others
5. Global Metachromatic Leukodystrophy (MLD) Treatment Market - by Treatment Type
  1. By AGT-183
  2. By GSK-2696274
  3. By DUOC-01
  4. By Others
6. Global Metachromatic Leukodystrophy (MLD) Treatment Market - by End User
  1. By Hospital
  2. By Clinic
  3. By Others
7. Global Metachromatic Leukodystrophy (MLD) Treatment Market - by region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
8. Market comparative analysis
North America Metachromatic Leukodystrophy (MLD) Treatment Market - Segment Analysis
1. Overview
2. North America Metachromatic Leukodystrophy (MLD) Treatment Market, 2016 - 2028 (USD Million)
3. North America Metachromatic Leukodystrophy (MLD) Treatment Market, by Type
  1. By Late Infantile MLD
  2. By Juvenile MLD
  3. By Adult MLD
4. North America Metachromatic Leukodystrophy (MLD) Treatment Market, by Diagnosis
  1. By Blood tests
  2. By Genetic tests
  3. By Nerve Conduction Study
  4. By Magnetic Resonance Imaging (MRI)
  5. By Psychological and Cognitive Tests
  6. By Others
5. North America Metachromatic Leukodystrophy (MLD) Treatment Market, by Treatment Type
  1. By AGT-183
  2. By GSK-2696274
  3. By DUOC-01
  4. By Others
6. North America Metachromatic Leukodystrophy (MLD) Treatment Market, by End User
  1. By Hospital
  2. By Clinic
  3. By Others
7. North America Metachromatic Leukodystrophy (MLD) Treatment Market, by Country
  1. U.S.
    1. U.S. Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. U.S. Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. U.S. Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. U.S. Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  2. Canada
    1. Canada Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. Canada Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. Canada Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. Canada Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  3. Mexico
    1. Mexico Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. Mexico Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. Mexico Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. Mexico Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
Europe Metachromatic Leukodystrophy (MLD) Treatment Market - Segment Analysis
1. Overview
2. Europe Metachromatic Leukodystrophy (MLD) Treatment Market, 2016 - 2028 (USD Million)
3. Europe Metachromatic Leukodystrophy (MLD) Treatment Market, by Type
  1. By Late Infantile MLD
  2. By Juvenile MLD
  3. By Adult MLD
4. Europe Metachromatic Leukodystrophy (MLD) Treatment Market, by Diagnosis
  1. By Blood tests
  2. By Genetic tests
  3. By Nerve Conduction Study
  4. By Magnetic Resonance Imaging (MRI)
  5. By Psychological and Cognitive Tests
  6. By Others
5. Europe Metachromatic Leukodystrophy (MLD) Treatment Market, by Treatment Type
  1. By AGT-183
  2. By GSK-2696274
  3. By DUOC-01
  4. By Others
6. Europe Metachromatic Leukodystrophy (MLD) Treatment Market, by End User
  1. By Hospital
  2. By Clinic
  3. By Others
7. Europe Metachromatic Leukodystrophy (MLD) Treatment Market, by Country
  1. Germany
    1. Germany Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. Germany Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. Germany Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. Germany Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  2. UK
    1. UK Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. UK Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. UK Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. UK Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  3. France
    1. France Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. France Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. France Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. France Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  4. Spain
    1. Spain Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. Spain Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. Spain Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. Spain Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  5. Italy
    1. Italy Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. Italy Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. Italy Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. Italy Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  6. BENELUX
    1. BENELUX Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. BENELUX Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. BENELUX Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. BENELUX Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  7. Rest of Europe
    1. Rest Of Europe Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. Rest Of Europe Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. Rest Of Europe Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. Rest Of Europe Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market - Segment Analysis
1. Overview
2. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market, 2016 - 2028 (USD Million)
3. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market, by Type
  1. By Late Infantile MLD
  2. By Juvenile MLD
  3. By Adult MLD
4. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market, by Diagnosis
  1. By Blood tests
  2. By Genetic tests
  3. By Nerve Conduction Study
  4. By Magnetic Resonance Imaging (MRI)
  5. By Psychological and Cognitive Tests
  6. By Others
5. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market, by Treatment Type
  1. By AGT-183
  2. By GSK-2696274
  3. By DUOC-01
  4. By Others
6. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market, by End User
  1. By Hospital
  2. By Clinic
  3. By Others
7. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market, by Country
  1. China
    1. China Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. China Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. China Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. China Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  2. Japan
    1. Japan Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. Japan Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. Japan Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. Japan Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  3. India
    1. India Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. India Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. India Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. India Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  4. South Korea
    1. South Korea Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. South Korea Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. South Korea Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. South Korea Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  5. South East Asia
    1. South East Asia Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. South East Asia Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. South East Asia Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. South East Asia Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  6. Rest of Asia Pacific
    1. Rest of Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. Rest of Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. Rest of Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. Rest of Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
Latin America Metachromatic Leukodystrophy (MLD) Treatment Market - Segment Analysis
1. Overview
2. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market, 2016 - 2028 (USD Million)
3. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market, by Type
  1. By Late Infantile MLD
  2. By Juvenile MLD
  3. By Adult MLD
4. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market, by Diagnosis
  1. By Blood tests
  2. By Genetic tests
  3. By Nerve Conduction Study
  4. By Magnetic Resonance Imaging (MRI)
  5. By Psychological and Cognitive Tests
  6. By Others
5. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market, by Treatment Type
  1. By AGT-183
  2. By GSK-2696274
  3. By DUOC-01
  4. By Others
6. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market, by End User
  1. By Hospital
  2. By Clinic
  3. By Others
7. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market, by Country
  1. Brazil
    1. Brazil Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. Brazil Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. Brazil Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. Brazil Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  2. Argentina
    1. Argentina Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. Argentina Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. Argentina Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. Argentina Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  3. Rest of Latin America
    1. Rest of Latin America Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. Rest of Latin America Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. Rest of Latin America Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. Rest of Latin America Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market - Segment Analysis
1. Overview
2. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market, 2016 - 2028 (USD Million)
3. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market, by Type
  1. By Late Infantile MLD
  2. By Juvenile MLD
  3. By Adult MLD
4. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market, by Diagnosis
  1. By Blood tests
  2. By Genetic tests
  3. By Nerve Conduction Study
  4. By Magnetic Resonance Imaging (MRI)
  5. By Psychological and Cognitive Tests
  6. By Others
5. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market, by Treatment Type
  1. By AGT-183
  2. By GSK-2696274
  3. By DUOC-01
  4. By Others
6. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market, by End User
  1. By Hospital
  2. By Clinic
  3. By Others
7. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market, by Country
  1. GCC Countries
    1. GCC Countries Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. GCC Countries Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. GCC Countries Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. GCC Countries Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  2. South Africa
    1. South Africa Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. South Africa Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. South Africa Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. South Africa Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
  3. Rest of Middle East & Africa
    1. Rest of Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market, By Type
      1. By Late Infantile MLD
      2. By Juvenile MLD
      3. By Adult MLD
    2. Rest of Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market, By Diagnosis
      1. By Blood tests
      2. By Genetic tests
      3. By Nerve Conduction Study
      4. By Magnetic Resonance Imaging (MRI)
      5. By Psychological and Cognitive Tests
      6. By Others
    3. Rest of Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market, By Treatment Type
      1. By AGT-183
      2. By GSK-2696274
      3. By DUOC-01
      4. By Others
    4. Rest of Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market, By End User
      1. By Hospital
      2. By Clinic
      3. By Others
Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Marketing Stratagy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Competative Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Company Profiles
1. ArmaGen Inc
2. GlaxoSmithKline plc
3. Takeda Pharmaceutical Company Limited
4. Orchard Therapeutics plc
5. Magenta Therapeutics
6. Recursion Pharmaceuticals Inc.
7. RegenxBio Inc.
8. Sanofi Genzyme
9. Abeona Therapeutics
10. bluebird bio
11. Lysogenes
Key Primary Respondents - VERBATIM
Discussion Guide
Customization Offered
Annexure
List of Figures
List of Tables
List of Abbreviations

FAQ

Frequently Asked Question

What is the global demand for Metachromatic Leukodystrophy (MLD) Treatment in terms of revenue?

The global Metachromatic Leukodystrophy (MLD) Treatment valued at USD 2.3 Billion in 2024 and is expected to reach USD 4.11 Billion in 2035 growing at a CAGR of 5.4%.

Which are the prominent players in the market?

The prominent players in the market are ArmaGen Inc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc, Magenta Therapeutics, Recursion Pharmaceuticals Inc., RegenxBio Inc., Sanofi Genzyme, Abeona Therapeutics, bluebird bio, Lysogenes.

At what CAGR is the market projected to grow within the forecast period?

The market is project to grow at a CAGR of 5.4% between 2025 and 2035.

What are the driving factors fueling the growth of the market.

The driving factors of the Metachromatic Leukodystrophy (MLD) Treatment include

Which region accounted for the largest share in the market?

North America was the leading regional segment of the Metachromatic Leukodystrophy (MLD) Treatment in 2024.

Metachromatic Leukodystrophy (MLD) Treatment Market

Metachromatic Leukodystrophy (MLD) Treatment Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Metachromatic Leukodystrophy (MLD) Treatment in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Quick Links

For Buying Inquiry

Metachromatic Leukodystrophy (MLD) Treatment Market

Metachromatic Leukodystrophy (MLD) Treatment Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Metachromatic Leukodystrophy (MLD) Treatment in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Related Reports

Request Sample Report for Metachromatic Leukodystrophy (MLD) Treatment Market

Vantage Point Interactive Dashboard